We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Allergan Snags Two Investigational Merck Migraine Therapies for $250 Million
Allergan Snags Two Investigational Merck Migraine Therapies for $250 Million
Allergan will pay $250 million to acquire the worldwide rights to two of Merck’s investigational small molecule oral calcitonin gene-related peptide (CGRP) antagonists for use against migraines.